#605: Bridging the AI Divide: Regulatory Trends, Industry Innovation, and the Future of AI in Pharma & Biotech

Wednesday, June 17, 2026 10:15 AM to 11:30 AM · 1 hr. 15 min. (America/New_York)
109AB
03: Data-Tech-AI

Information

Artificial Intelligence is redefining pharma and biotech. This session contrasts AI-native and traditional models, examines FDA, EMA, and EU AI frameworks, and delivers strategies to ensure credible, compliant AI use in regulatory decision-making.
CE
ACPECMERN
Session Level
Intermediate
Featured Topics
Artificial Intelligence
Learning Objectives
Differentiate between AI-native and traditional pharma/biotech models in drug development; Assess regulatory expectations for AI from FDA, EMA, and the EU AI Act; Apply strategies to establish AI model credibility for regulatory decision-making.

Registered attendees

AF
Aaron Fier
Director of Regulatory Information ManagementModerna
Aaron Josephson
Aaron Josephson
Vice President & Head of Global External RelationsSamsung Bioepis
AS
Aaron Smith
Senior Manager, Regulatory OperationsImmunocore LLC